SCHEDULE 13G/A: FMR LLC Reduces Stake in Allogene Therapeutics Below 5% Threshold

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 4.9% in Allogene Therapeutics Inc., signaling a reduction in their stake below the 5% reporting threshold.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Allogene Therapeutics Inc.
• As of February 28, 2025, FMR LLC and Abigail P. Johnson collectively beneficially own 10,225,851 shares of Allogene Therapeutics Inc. common stock.
• This aggregate amount represents 4.9% of the total outstanding common stock of Allogene Therapeutics Inc.
• FMR LLC holds sole voting power over 10,217,129 shares and sole dispositive power over 10,225,851 shares.
• Abigail P. Johnson holds sole dispositive power over 10,225,851 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain information that inherently suggests positive or negative sentiment regarding the issuer's performance or prospects. The reduction below 5% is a neutral reporting event, though it implies a reduction in stake.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional investor, FMR LLC (Fidelity), indicating its passive ownership stake in a biotechnology company. The reduction of their stake below the 5% threshold means they are no longer considered a significant beneficial owner requiring more detailed Schedule 13D filings, which are typically associated with activist intentions.

Stakeholder Impact

• Shareholders: The reduction of FMR LLC's stake below 5% may be interpreted by some shareholders as a signal of reduced institutional confidence, though it is a passive investment and not indicative of active divestment for performance reasons. It also means FMR LLC is no longer a 5%+ reporting entity.

Key Dates

Keywords

Allogene Therapeutics Inc., FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Institutional Investor, Ownership Stake